Stockreport

Annexon's ANX005 offers improvement in Phase III GBS trial [Yahoo! Finance]

Annexon, Inc. - common stock  (ANNX) 
PDF The placebo-controlled, randomised trial enrolled 241 patients in Bangladesh and the Philippines to assess two 30mg/kg and 75mg/kg doses of of ANX005. According to th [Read more]